The Breakthrough: Immunotherapy and the Race to Cure Cancer
KENTUCKY AUTHOR FORUM
CHARLES GRAEBER WITH DR. THOMAS GAJEWSKI
THURSDAY, NOVEMBER 15
ATTENTION NEW SCHEDULE:
6PM- Carmichael’s book sale, Brown-Forman wine & cheese in the North Lobby
7PM – Interview in the Bomhard Theater
8PM – Audience Q & A
(A $25 ticket includes the above three events)
8:30PM – Dinner in honor of author and interviewer at KMAC
(A $120 package ticket includes above three events plus dinner
$50 deductible, with proceeds to nonprofit Kentucky Author Forum)
ABOUT THIS AUTHOR:
Charles Graeber is an award-winning journalist and the author of the Edgar-nominated New York Times bestseller “The Good Nurse”.
He is also a contributor to numerous publications including Wired, GQ, The New Yorker, New York Magazine, Vogue, Outside Magazine, Men’s Journal, Bloomberg Businessweek, Travel + Leisure, and The New York Times, and an occasional guest on CNN, NPR, and other radio programs. His work has been honored with the Overseas Press Club award for outstanding international journalism, the New York Press Club prize for the year’s best magazine spot news reportage, several National Magazine Award-nominations, and inclusion in numerous anthologies.
ABOUT THIS BOOK:
Charles Graeber, award-winning journalist and the author of the Edgar-nominated New York Times bestseller “The Good Nurse” details the astonishing scientific discovery of the code to unleashing the human immune system to fight — and possibly even cure — cancer.
In THE BREAKTHROUGH, Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step-harnessing the wealth of new information to create modern and more effective patient therapies-is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease.
Groundbreaking, riveting, and expertly told, THE BREAKTHROUGH is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, as told through the experiences of the patients, physicians, and cancer immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history.
ABOUT THE INTERVIEWER:
Thomas Gajewski, MD, PhD is Professor in the Departments of Pathology and Medicine. He oversees the melanoma oncology clinic, is Leader of the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center and directs the Human Immunologic Monitoring core facility.
His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease. He also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials.
Dr. Gajewski has published more than 200 papers on these subjects, has served on numerous NIH grant review panels, is an editor for Cancer Research and Journal for Immunotherapy of Cancer, is on the Program Committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), and is past president of the Society for Immunotherapy of Cancer. He was recently awarded the first American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy.
As his laboratory work leads to new potential immunotherapies for cancer, Dr. Gajewski is involved with several early biotech companies. He scientific co-founder of Jounce Therapeutics, and has licensing arrangements with Aduro Biotech and Evelo, a new company focused on the microbiome and cancer.